Aldeyra Therapeutics (NASDAQ:ALDX) Rating Reiterated by HC Wainwright

HC Wainwright restated their buy rating on shares of Aldeyra Therapeutics (NASDAQ:ALDX) in a report issued on Friday morning, Benzinga reports. They currently have a $10.00 price target on the biotechnology company’s stock.

Other equities analysts have also issued reports about the company. StockNews.com lowered Aldeyra Therapeutics from a hold rating to a sell rating in a research note on Wednesday, May 22nd. Oppenheimer reaffirmed an outperform rating and issued a $10.00 price objective on shares of Aldeyra Therapeutics in a research note on Monday, May 6th.

Aldeyra Therapeutics Stock Performance

NASDAQ:ALDX opened at $3.52 on Friday. The stock’s 50-day moving average is $3.70 and its 200-day moving average is $3.64. Aldeyra Therapeutics has a 1-year low of $1.42 and a 1-year high of $8.38.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.06). On average, research analysts forecast that Aldeyra Therapeutics will post -0.23 earnings per share for the current year.

Hedge Funds Weigh In On Aldeyra Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new position in shares of Aldeyra Therapeutics during the 4th quarter worth approximately $39,000. International Assets Investment Management LLC boosted its holdings in shares of Aldeyra Therapeutics by 319.2% during the 4th quarter. International Assets Investment Management LLC now owns 205,335 shares of the biotechnology company’s stock worth $7,210,000 after buying an additional 156,353 shares in the last quarter. Prime Capital Investment Advisors LLC bought a new position in shares of Aldeyra Therapeutics during the 4th quarter worth approximately $35,000. Strs Ohio boosted its holdings in shares of Aldeyra Therapeutics by 270.8% during the 4th quarter. Strs Ohio now owns 87,500 shares of the biotechnology company’s stock worth $307,000 after buying an additional 63,900 shares in the last quarter. Finally, Cornercap Investment Counsel Inc. bought a new position in shares of Aldeyra Therapeutics during the 4th quarter worth approximately $216,000. 59.71% of the stock is owned by institutional investors and hedge funds.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.